Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.
Journal: Cancer research communications
Published: July 20, 2026
Trends in Patient Misperception and Decisional Regret During Treatment for Advanced Cancer: An Exploratory, Single-Center Study of English-Speaking Adults.
Journal: Journal of patient experience
Published: March 26, 2026
ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy.
Journal: European urology focus
Published: February 27, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 22, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 23, 2025
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: September 15, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.
Journal: bioRxiv : the preprint server for biology
Published: August 08, 2025
Castration Resistance Accelerates Prostate Cancer Kinetics.
Journal: The Prostate
Published: August 07, 2025
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 25, 2025
Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer.
Journal: Molecular cancer therapeutics
Published: April 26, 2025
Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol.
Journal: Frontiers in sports and active living
Published: April 03, 2025
Last Updated: 09/26/2026